Determination of Resistance Profiles to Fluoroquinolones and Characterization of Genetic Determinants of Resistance in Campylobacter spp. Isolated from Diarrheal Faeces in Children in the City of Makokou

Campylobacter is a zoonotic bacterium and the leading cause of bacterial gastroenteritis in humans and animals in several countries. It is managed through antibiotic therapy, including macrolides (erythromycin) and fluoroquinolones (ciprofloxacin), which is the drug of choice. The aim of this study was to investigate the phenotypic resistance profile and the molecular determinants potentially associated with fluoroquinolone resistance in Campylobacter isolates obtained from diarrhoeal faeces of children under 5 years of age in Makokou, Gabon. The susceptibility of 116 Campylobacter isolates was evaluated against ciprofloxacin and pefloxacin (second-generation fluoroquinolones) and levofloxacin (third-generation fluoroquinolone). The genetic basis of any resistance to these compounds was determined by screening the chromosomal gyrA gene and the plasmid qnrA, qnrB and qnrS genes, which were detected using conventional PCR. Phenotypically, all isolates are resistant to all compounds (100%). Molecularly, the gyrA gene was amplified in 94.0% of the isolates, the qnrS gene in 51.7% (60/116), the qnrB gene in 4.3% (5/116), and the qnrA gene 0.0%. Furthermore, 52.6% (61/116) carried both the gyrA gene and at least one of the qnr genes detected. Campylobacter isolates showed total resistance to fluoroquinolones, suggesting a probable therapeutic deadlock with these molecules, possibly mediated by qnr genes. The detection of these genetic determinants suggests that plasmid-mediated transmission may contribute to the spread of resistant Campylobacter in various environments. However, given that conventional PCR only confirms the presence of the gyrA gene and not the specific mutations within the quinolone resistance-determining region (QRDR) that confer resistance, additional genomic sequencing is required to fully elucidate the mechanisms of resistance. This study consequently highlights the importance of monitoring the epidemiological evolution and resistance of Campylobacter isolates in order to optimize therapeutic management strategies.

Authors

Institutions

Publication Details

Journal
Microorganisms
Published
2026-11-18
DOI
https://doi.org/10.3390/microorganisms14112678
Primary Topic
Salmonella and Campylobacter epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Determination of Resistance Profiles to Fluoroquinolones and Characterization of Genetic Determinants of Resistance in Campylobacter spp. Isolated from Diarrheal Faeces in Children in the City of Makokou

Jean Fabrice Yala, Franck Mounioko, Ornella Zong Minko, Léonce Fauster Ondjiangui et al.
Microorganisms
Salmonella and Campylobacter epidemiology
article

Determination of Resistance Profiles to Fluoroquinolones and Characterization of Genetic Determinants of Resistance in Campylobacter spp. Isolated from Diarrheal Faeces in Children in the City of Makokou

Jean Fabrice Yala, Franck Mounioko, Ornella Zong Minko, Léonce Fauster Ondjiangui, Evrard Mayombo Ngoussou, José-Miguel Armesto Paula, Rolande Mabika Mabika, Junior Aymard Ondo-Nang
article en

Abstract

Campylobacter is a zoonotic bacterium and the leading cause of bacterial gastroenteritis in humans and animals in several countries. It is managed through antibiotic therapy, including macrolides (erythromycin) and fluoroquinolones (ciprofloxacin), which is the drug of choice. The aim of this study was to investigate the phenotypic resistance profile and the molecular determinants potentially associated with fluoroquinolone resistance in Campylobacter isolates obtained from diarrhoeal faeces of children under 5 years of age in Makokou, Gabon. The susceptibility of 116 Campylobacter isolates was evaluated against ciprofloxacin and pefloxacin (second-generation fluoroquinolones) and levofloxacin (third-generation fluoroquinolone). The genetic basis of any resistance to these compounds was determined by screening the chromosomal gyrA gene and the plasmid qnrA, qnrB and qnrS genes, which were detected using conventional PCR. Phenotypically, all isolates are resistant to all compounds (100%). Molecularly, the gyrA gene was amplified in 94.0% of the isolates, the qnrS gene in 51.7% (60/116), the qnrB gene in 4.3% (5/116), and the qnrA gene 0.0%. Furthermore, 52.6% (61/116) carried both the gyrA gene and at least one of the qnr genes detected. Campylobacter isolates showed total resistance to fluoroquinolones, suggesting a probable therapeutic deadlock with these molecules, possibly mediated by qnr genes. The detection of these genetic determinants suggests that plasmid-mediated transmission may contribute to the spread of resistant Campylobacter in various environments. However, given that conventional PCR only confirms the presence of the gyrA gene and not the specific mutations within the quinolone resistance-determining region (QRDR) that confer resistance, additional genomic sequencing is required to fully elucidate the mechanisms of resistance. This study consequently highlights the importance of monitoring the epidemiological evolution and resistance of Campylobacter isolates in order to optimize therapeutic management strategies.

MicroorganismsVol. 14(11)
Centre International de Recherches Médicales de Franceville (GA), Université des Sciences et Techniques de Masuku (GA)
Good health and well-being, Zero hunger
Salmonella and Campylobacter epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon